MDWerks Appoints Jeff Hopmayer to Board of Directors as Molecular Targeting Technology Platform Expands Across Industrial Markets

MDWerks, Inc. (OTCQB: MDWK), a molecular targeting technology company commercializing proprietary energy-wave platforms that selectively influence target molecules to improve industrial processes, today announced the appointment of Jeff Hopmayer to its Board of Directors.

Hopmayer joins the Board as MDWerks enters a pivotal stage in its evolution—from technology development to commercial execution. Supported by a growing global patent estate, an independently appraised intellectual property portfolio valued at approximately $400 million, signed commercial contracts, and customer deployments that began in Q2 2026, the Company is executing a strategy centered on recurring licensing revenue, scalable industrial applications, and long-term shareholder value.

MDWerks has reached an important commercial inflection point, moving beyond laboratory validation toward initial commercial deployments supported by customer contracts and a growing pipeline of opportunities across multiple industries. Rather than commercializing a single product, the Company is advancing a molecular targeting platform capable of enabling solutions across numerous industrial markets.

The Company's technology platform is protected by a broad patent estate of issued and pending patents and patent applications worldwide, creating multiple layers of protection around its proprietary molecular targeting processes, equipment, and industrial applications. This intellectual property foundation supports a scalable licensing model designed to generate recurring revenue as the technology expands into new commercial verticals.